Literature DB >> 30376356

Sputum Microbiome Is Associated with 1-Year Mortality after Chronic Obstructive Pulmonary Disease Hospitalizations.

Fernando Sergio Leitao Filho1, Nawaf M Alotaibi1,2, David Ngan1, Sheena Tam1, Julia Yang1, Zsuzsanna Hollander1,3, Virginia Chen1,3, J Mark FitzGerald4, Corey Nislow5, Janice M Leung1,4, S F Paul Man1,4, Don D Sin1,4.   

Abstract

Rationale: Lung dysbiosis promotes airway inflammation and decreased local immunity, potentially playing a role in the pathogenesis of acute exacerbations of chronic obstructive pulmonary disease (AECOPD).
Objectives: We sought to determine the relationship between sputum microbiome at the time of AECOPD hospitalization and 1-year mortality in a COPD cohort.
Methods: We used sputum samples from 102 patients hospitalized because of AECOPD. All subjects were followed for 1 year after discharge. The microbiome profile was assessed through sequencing of 16S rRNA gene. Microbiome analyses were performed according to 1-year mortality status. To investigate the effect of α-diversity measures and taxon features on time to death, we applied Cox proportional hazards regression models and obtained hazard ratios (HRs) associated with these variables. Measurements and Main
Results: We observed significantly lower values of α-diversity (richness, Shannon index, evenness, and Faith's Phylogenetic Diversity) among nonsurvivors (n = 19, 18.6%) than survivors (n = 83, 81.4%). β-Diversity analysis also demonstrated significant differences between both groups (adjusted permutational multivariate ANOVA, P = 0.010). The survivors had a higher relative abundance of Veillonella; in contrast, nonsurvivors had a higher abundance of Staphylococcus. The adjusted HRs for 1-year mortality increased significantly with decreasing α-diversity. We also observed lower survival among patients in whom sputum samples were negative for Veillonella (HR, 13.5; 95% confidence interval, 4.2-43.9; P < 0.001) or positive for Staphylococcus (HR, 7.3; 95% confidence interval, 1.6-33.2; P = 0.01). Conclusions: The microbiome profile of sputum in AECOPD is associated with 1-year mortality and may be used to identify subjects with a poor prognosis at the time of hospitalization.

Entities:  

Keywords:  COPD; acute exacerbations; dysbiosis; mortality; sputum microbiome

Mesh:

Year:  2019        PMID: 30376356     DOI: 10.1164/rccm.201806-1135OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  30 in total

Review 1.  Methods in Lung Microbiome Research.

Authors:  Sharon M Carney; Jose C Clemente; Michael J Cox; Robert P Dickson; Yvonne J Huang; Georgios D Kitsios; Kirsten M Kloepfer; Janice M Leung; Tricia D LeVan; Philip L Molyneaux; Bethany B Moore; David N O'Dwyer; Leopoldo N Segal; Stavros Garantziotis
Journal:  Am J Respir Cell Mol Biol       Date:  2020-03       Impact factor: 6.914

2.  Lung Microbiota Predict Clinical Outcomes in Critically Ill Patients.

Authors:  Robert P Dickson; Marcus J Schultz; Tom van der Poll; Laura R Schouten; Nicole R Falkowski; Jenna E Luth; Michael W Sjoding; Christopher A Brown; Rishi Chanderraj; Gary B Huffnagle; Lieuwe D J Bos
Journal:  Am J Respir Crit Care Med       Date:  2020-03-01       Impact factor: 21.405

3.  Lung microbiota predict chronic rejection in healthy lung transplant recipients: a prospective cohort study.

Authors:  Michael P Combs; David S Wheeler; Jenna E Luth; Nicole R Falkowski; Natalie M Walker; John R Erb-Downward; Vibha N Lama; Robert P Dickson
Journal:  Lancet Respir Med       Date:  2021-01-15       Impact factor: 30.700

4.  Whole lung tissue is the preferred sampling method for amplicon-based characterization of murine lung microbiota.

Authors:  Jennifer M Baker; Kevin J Hinkle; Roderick A McDonald; Christopher A Brown; Nicole R Falkowski; Gary B Huffnagle; Robert P Dickson
Journal:  Microbiome       Date:  2021-05-05       Impact factor: 14.650

Review 5.  The lung microbiome: progress and promise.

Authors:  Samantha A Whiteside; John E McGinniss; Ronald G Collman
Journal:  J Clin Invest       Date:  2021-08-02       Impact factor: 19.456

Review 6.  Protein Biomarkers for COPD Outcomes.

Authors:  Karina A Serban; Katherine A Pratte; Russell P Bowler
Journal:  Chest       Date:  2021-01-09       Impact factor: 10.262

7.  Chronic obstructive pulmonary disease upper airway microbiota alpha diversity is associated with exacerbation phenotype: a case-control observational study.

Authors:  Alexa A Pragman; Katherine A Knutson; Trevor J Gould; Richard E Isaacson; Cavan S Reilly; Chris H Wendt
Journal:  Respir Res       Date:  2019-06-07

8.  Patterns in the longitudinal oropharyngeal microbiome evolution related to ventilator-associated pneumonia.

Authors:  Rami Sommerstein; Tobias M Merz; Sabine Berger; Julia G Kraemer; Jonas Marschall; Markus Hilty
Journal:  Antimicrob Resist Infect Control       Date:  2019-05-22       Impact factor: 4.887

9.  Could the Sputum Microbiota Be a Biomarker That Predicts Mortality after Acute Exacerbations of Chronic Obstructive Pulmonary Disease?

Authors:  Jun-Chieh J Tsay; Leopoldo N Segal
Journal:  Am J Respir Crit Care Med       Date:  2019-05-15       Impact factor: 21.405

10.  MULTI-PHACET: multidimensional clinical phenotyping of hospitalised acute COPD exacerbations.

Authors:  Martin I MacDonald; Christian R Osadnik; Lauren Bulfin; Elizabeth Leahy; Paul Leong; Eskandarain Shafuddin; Kais Hamza; Paul T King; Philip G Bardin
Journal:  ERJ Open Res       Date:  2021-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.